| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8711847 | Annals of Allergy, Asthma & Immunology | 2018 | 6 Pages |
Abstract
Our study found that omalizumab is a well-tolerated and effective therapy for elderly patients with nonsedating H1-antihistamine-refractory CSU.
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Eustachio MD, Luca MD, PhD, MSc, Elisabetta MD, PhD, Walter Giorgio MD, Aikaterini MD, PhD,